Clinical Trials on High-risk Non-muscle Invasive Bladder Cancer

Total 823 results

Jecho Biopharmaceuticals Co., Ltd.

Recruiting

A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer. (JL19001-NMIBC)

High Risk Non-muscle Invasive Bladder Cancer

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy

High-risk Non-muscle-invasive Bladder Cancer

China
Natera, Inc.

Recruiting

Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC) (SCORE-NMIBC)

NMIBC | Non-Muscle Invasive Bladder Cancer | High-risk Non-Muscle Invasive Bladder Cancer

United States
University of Roma La Sapienza

Recruiting

Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs) (CUT-less)

Non-muscle-invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial Carcinoma | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

Italy
RemeGen Co., Ltd.

Recruiting

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

High-risk Non-muscle Invasive Bladder Cancer

China

This is a preview

Log in or create a free account to see all matching trials and use the full search.

Log in Register

Subscribe